Skip navigation
Skip navigation
You are using an outdated browser. Please upgrade your browser.

British Tech Firm Gets Green Light on Patent

British technology start-up Ablatus has received a new UK patent for their enhanced ablation technology. The move signifies hope for up to 12 million UK women affected by uterine fibroids, offering a new minimally invasive treatment option with global potential. The uterine fibroids device market is projected to reach $15.6Bn in 2032.

The new patent allows the enablement of additional direct current, offering the potential for improved patient outcomes and better quality of life across a range of clinical indications. Fibroids is a highly prevalent condition with around 80% of women globally having fibroids by the age of fifty. Treatment development lacks funding and treatment options that are minimally invasive and fertility-preserving are lacking. Uterine fibroids can cause debilitating pain, heavy menstrual bleeding, abdominal swelling, and complications during pregnancy and labour. These conditions impose a staggering up to $34.4 billion annually in the US alone.

Dr. Chung Looi, CEO of Ablatus Therapeutics, said: “Our mission is to enable millions of women access to a safe and cost-effective treatment for uterine fibroids so they can enjoy a better quality of life whilst preserving their fertility. This is a vastly underfunded condition in the vastly underfunded sector of women’s health and enough is enough. Securing this patent on our technology gives hope that future generations will not have to endure unnecessary suffering.”

How it works:

• Uterine fibroids are the main cause of hysterectomy – 13k per year in the UK
• Current treatments are mainly hormone pills or invasive surgery
• Most women delay treatment for up to three years with 80% wanting to avoid invasive surgery and fear for fertility, facing crippling pain, debilitating symptoms and increasing risk of complication
• Ablation technology destroys tumours and at the site
• Minimally invasive
• Day case outpatient procedure (reducing costs of inpatient stays)
• A probe (needle) is inserted and uses radiofrequency (RFA) tech to penetrate the centre and destroy tumours

Ablatus is a British women's technology health company born out of the Norfolk and Norwich University Hospitals NHS Foundation Trust. Currently in advanced development, Luna targets fibroids with their patented enhanced ablation tech. Luna is grant backed by Innovate UK with an RTO Catapult Grant, and an Global Explorer's grant. Ablatus has previously secured already £3 million of funding from investors included by Mercia Ventures, Low Carbon Innovation Fund, MedTech Accelerator and angel investors, and now open to welcome new investors to accelerate growth including the community given how prevalent fibroids are via a crowd funding campaign.

For more information please contact Helen Trevorrow on 0794 000 9138 or email

- Ends –

About Ablatus

Check out the crowdfunding campaign to accelerate their journey - smart and impactful investment to shape women's health.
Ablatus’ vision is to offer patients improved outcomes and better quality of life across a range of clinical conditions through the application of enhanced soft tissue radiofrequency ablation (RFA) technology.

The use of radiofrequency ablation is now an established non-surgical minimally invasive procedure to treat soft tissue tumours, fibroids and other related conditions. Our technology, Bimodal Electric Tissue Ablation, or BETA for short, is an enhanced form of tissue ablation whereby abnormal tissues can be destroyed in situ, as an alternative to surgery. Standard RFA has limitations in terms of the size of tumours or fibroids it can address, but BETA can improve upon these, potentially allowing the ablation of previously untreatable tumours and fibroids whilst protecting healthy tissue.

The company was founded in 2015 and was the first spin-out from the Norfolk and Norwich University Hospital NHS Foundation Trust, where the BETA technology was invented.
Ablatus has been certified to ISO 13485:2016 following successful audits with BSI. ISO 13485 is a global standard in quality management systems for medical devices that supports policies and processes across the entire business.

This press release was distributed by ResponseSource Press Release Wire on behalf of Green Row Communications in the following categories: Health, Business & Finance, Medical & Pharmaceutical, for more information visit